Dendritic cell (DC) activation is a critical event for the induction of an immune response to haptens. Although signaling pathways such as mitogen-activated protein kinase (MAPK) family members have been reported to play a role in DC activation by haptens, little is known about the implication of the nuclear factor kappa B (NF-kB) pathway. In this work, we showed that NiSO 4 induced the expression of HLA-DR, CD83, CD86, and CD40 and the production of interleukin (IL)-8, IL-6, and IL-12p40 in human DCs, whereas 1-chloro-2,4-dinitrobenzene (DNCB) induced mainly the expression of CD83 and CD86 and the production of IL-8. NiSO 4 but not DNCB was able to activate the degradation of IkB-a leading to the binding of the p65 subunit of NF-kB on specific DNA probes. Inhibition of the NF-kB pathway using BAY 11-7085 prevents both CD40 and HLA-DR expression and cytokine production induced by NiSO 4 . However, BAY 11-7085 only partially inhibited CD86 and CD83 expression induced by NiSO 4 . In addition, p38 MAPK and NF-kB were independently activated by NiSO 4 since SB203580 did not inhibit NF-kB activation by NiSO 4 . Interestingly, we also showed that DNCB inhibited the degradation of IkB-a induced by tumor necrosis factor-a leading to alteration of CD40, HLA-DR, and CD83 expression but not of CD86 and CCR7. Extensive modifications of DC phenotype by NiSO 4 in comparison to DNCB are probably the consequence of NF-kB activation by NiSO 4 but not by DNCB.
Allergic contact hypersensitivity is a T-cell immune response resulting from dendritic cell (DC) activation in the skin by small molecular weight compounds termed haptens. Once DCs capture the hapten in the skin, they migrate to the draining lymph nodes and present the hapten associated with major histocompatibility complex (MHC) Class II molecules to naïve T lymphocytes leading to the clonal expansion of hapten-specific T lymphocytes (Bour et al., 1995; Rougier et al., 2000) .
Langerhans cells (LC) isolated from skin explants treated with haptens have shown upregulation of CD86, CD54, and HLA-DR expression (Tuschl and Kovac, 2001 ). However, the use of LC from skin samples is limited in term of low LC yields and sometimes spontaneous maturation occurs during the extraction procedure. The discovery of methods for in vitro generation of immature DC constituted a useful advance to study molecular mechanisms involved in DC maturation. DC can be generated either from monocytes (Sallusto and Lanzavecchia, 1994) or CD34 þ hematopoietic progenitors obtained from neonatal cord blood (Caux et al., 1996) . These models offered new insight for studying DC response to contact sensitizers (CS). Upon treatment with CS, DCs show upregulation of markers such as MHC Class II molecules, CD54, CCR7, CD86, CD83, CD80, and CD40 (Aiba et al., 1997 (Aiba et al., , 2000 Arrighi et al., 2001; Boisleve et al., 2004; De Smedt et al., 2001 Staquet et al., 2004; Tuschl et al., 2000) . These phenotypical changes are accompanied by cytokine production such as interleukin (IL)-6, tumor necrosis factor (TNF)-a, IL-8, and IL-1b (Aiba et al., 1997; De Smedt et al., 2001 Tuschl et al., 2000; Verheyen et al., 2005) . In addition, not only cultured human LC but also in vitro generated human DC could prime T cells to induce a proliferative response to strong allergens (Rougier et al., 2000) . All these results show that CS are able to induce the activation of human DC in spite of the lack of skin environment, suggesting that DCs act as a crucial ''sensor'' of danger signals including low molecular weight compounds (Gallucci and Matzinger, 2001) .
One purpose of our work is to elucidate if simple chemicals are able to induce DC maturation in a manner similar to the one observed with well described danger signals such as lipopolysaccharides (LPS) and proinflammatory cytokines (Arrighi et al., 2001; Boisleve et al., 2004; Verhasselt et al., 1997) . To activate DC, danger signals use several common signal transduction pathways with major roles for mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B (NF-jB). However, signaling involved in CS-induced DC maturation remains to be clarified. Kühn et al. (1998) have demonstrated an increase in tyrosine-phosphorylated proteins after stimulation with strong CS. Several authors have also reported the role of members of the MAPK family, namely, extracellular regulated kinases, jun kinases (JNK), and p38 MAPK in DC maturation induced by CS (Aiba et al., 2003; Arrighi et al., 2001; Boisleve et al., 2004 Boisleve et al., , 2005 . Indeed, in monocytederived DC (MoDC), p38 MAPK has been demonstrated to be critical for the upregulation of CD80, CD83, and to a lesser extent CD86 but not for CD1a, CD40, and HLA-DR expression (Arrighi et al., 2001) .
In contrast to the MAPK pathway, the involvement of the NF-jB pathway in response to CS is still poorly understood. Attar et al. (1998) have shown that mutation of the IjB-b gene in mice impaired delayed type hypersensitivity in response to fluorescence isothiocyanate (FITC). Nickel and cobalt, that are well known sensitizers, have been shown to induce NF-jB binding activity in human endothelial cells (Goebeler et al., 1995) . Aiba et al. (2003) have also shown that NiSO 4 can activate NF-jB in MoDC. However, to date there is no report evaluating the role of NF-jB in DC maturation upon hapten exposure.
In unstimulated cells, NF-jB-family proteins exist as heterodimers and homodimers that are sequestered in the cytoplasm by members of the IjB family. Upon cell stimulation, activation of IjB kinase (IKK) is observed leading to phosphorylation of IjB proteins on serine residues. The phosphorylation of IjB-a induced the dissociation of the NF-jB/IjB complex and subsequent ubiquitination and proteolysis of IjB-a by the proteasome. Free NF-jB heterodimers (p65/p50) can then translocate to the nucleus where they bind to NF-jB enhancer element of target genes. Signals such as Toll-Like Receptors (TLR) agonists or proinflammatory cytokines are known to activate NF-jB in DC leading to production or expression of many inflammatory cytokines, chemokines, immune receptors, and cell surface molecules (Verhasselt et al., 1999) .
NF-jB and MAPK pathways are the two major pathways involved in DC maturation induced by danger signals such as TLR agonists. Our hypothesis is that CS are perceived as danger signals by DC inducing their maturation. In this study, we investigated the role of NF-jB in phenotypic changes and cytokine production induced in response to NiSO 4 and DNCB. We choose these two haptens as prototypes of metallic and organic sensitizers. Our results show that NiSO 4 but not DNCB is able to induce NF-jB activation in CD34-derived DC (CD34-DC). This observation may explain phenotypical differences observed when DCs are treated with either NiSO 4 or DNCB.
MATERIALS AND METHODS
Preparing DC from human cord blood. Normal human umbilical cord blood was obtained from Biopredic (Rennes, France) and processed within 24 h. Cord blood samples were diluted 1:6 in phosphate-buffered saline (PBS). After Ficoll-Hypaque (Medium for Lymphocyte Isolation, Eurobio, Les Ulis, France) centrifugation (300 g for 30 min at 20°C), mononuclear cells were collected and washed three times in PBS supplemented with 2% of heatinactivated fetal bovine serum (FBS). Cord blood CD34 þ hematopoietic cells were isolated using MiniMACS separation columns (Miltenyi Biotec, Bergish, Germany) through magnetic positive selection using the direct CD34 progenitor cell isolation kit (Miltenyi Biotec). After purification, the isolated cells were 80-95% CD34 þ cells.
CD34
þ cells were adjusted to the concentration of 3 3 10 5 cells/ml and cultured at 37°C in a humidified 5% CO 2 atmosphere in RPMI 1640 Glutamax I medium, 10% FBS, 100 U/ml penicillin, 100 lg/ml streptomycin, 1mM sodium pyruvate (all from Gibco Invitrogen, Paisley, UK), and supplemented with 200 U/ml granulocyte-macrophage-colony stimulating factor, (GM-CSF) (Leucomax 400 a kind gift from Novartis, Rueil-Malmaison, France), 50 U/ml rhTNF-a (kindly provided by Dr Schmidt, Mainz, Germany) and 50 ng/ml Flt-3 Ligand (Flt-3L, PeproTech, Tebu, Le Perray-en-Yvelines, France). Cells were then cultured for 7 days.
Chemical exposure of immature DCs. After a culture period of 7 days, the cells were washed three times before treatment. Cells (1 3 10 6 cells/ml) were exposed to either NiSO 4 (Sigma, St Louis, MO) or DNCB (Sigma). After performing dose-response experiments, optimal concentrations of the two allergens were selected according to their impact on cell viability and on cell surface marker determined after 24 h of treatment. For cell viability, the highest concentration should not lead to a cell viability inferior to 75%. In the case of DNCB (25lM dissolved in dimethyl sulfoxide [DMSO] at final concentration of 0,05%), treatment was performed for only 30 min and cells were then washed three times and reincubated for different periods of time. In the case of NiSO 4 cells were treated according to the different times mentioned for each experiment. BAY 11-7085 (dissolved in DMSO, Calbiochem, AMD Biosciences, Darmstadt, Germany) was added 1 h before any treatment. SB203580 (dissolved in distilled water, Calbiochem) was added 30 min before treatment with NiSO 4 .
Immunoblotting. Western blot analysis was performed according to standard procedure, as previously described . Briefly, cells were washed with cold PBS 1X. Cell lysates were prepared by resuspending the cell pellet containing 2 3 10 6 cells in lysis buffer (20mM Tris pH 7.4, 137mM NaCl, 2mM ethylenediaminetetraacetic acid (EDTA), pH 7.4, 1% Triton X-100, 25mM b-glycerophosphate, 1mM Na 3 VO 4 , 2mM sodium pyrophosphate, 10% glycerol, 1mM phenylmethanesulphonylfluoride (PMSF), 10 lg/ml aprotinin, 10 lg/ml leupeptin, and 10 lg/ml pepstatin), incubated on ice for 20 min and followed by centrifugation at 17,600 g at 4°C for 20 min. Protein concentration was determined using the bicinchoninic acid assay (Sigma). Equal amount of proteins were subjected to 12.5% sodium dodecyl sulfatepolyacrylamide electrophoresis (SDS-PAGE). The proteins were transferred onto polyvinylidene difluoride membranes (Amersham Biosciences, Les Ulis, France) and the membranes were probed with the rabbit anti-IjB-a polyclonal Ab (C-21, Santa Cruz Biotechnology, Santa Cruz, CA) or the rabbit anti-phospho-p38 MAPK (Thr 180/Tyr 182) monoclonal Ab (3D7, Cell Signaling Technology, Ozyme, St-Quentin-en-Yveline, France) followed by goat anti-rabbit polyclonal Ab conjugated to horse radish peroxidase (Cell Signaling Technology). The membranes were stripped for the primary Abs and reprobed with Ab raised against total p38 MAPK as a loading control (p38 N20, Santa Cruz Biotechnology). The immunoblots were visualized by enhanced chemiluminescence (Amersham Biosciences). Densitometric analysis of the blots was performed using the Quantity One Software (Bio-Rad Laboratories, CA).
Flow cytometric analysis. Selected monoclonal antibodies (MoAb) were used to phenotype the DC population. DCs were analyzed with dual-color flow cytometry using PE-Cy5-labeled mouse anti-human CD86 MoAb (2331 (FUN-1) ), PE-labeled mouse anti-human CD83 MoAb (HB15e), Allophycocyanin (APC)-labeled mouse anti-human CD40 MoAb (5C3), FITC-labeled mouse antihuman HLA-DR (G46-6 (L243)), PE-Cy5-labeled mouse IgG1,j isotype control, PE-labeled mouse IgG1,j isotype control, APC-labeled mouse IgG1, j isotype control and FITC-labeled mouse IgG2a,j isotype control provided by BD Biosciences Pharmingen (San Diego, CA). The PE-labeled mouse antihuman CCR7 MoAb (150503) and the PE-labeled mouse IgG2a isotype control was purchased from R&D Systems (Lille, France). The labeling procedure was as follows: cells were washed in cold PBS (containing 0.5% bovine serum albumin [BSA] ) and stained with antibodies in the dark on ice for 30 min, washed twice with cold PBS (containing 0.5% BSA), once with PBS without BSA, and resuspended in PBS. Cells were then analyzed on a FACScalibur cell analyzer (Becton Dickinson, San Jose, CA) using the CellQuest Software (Becton Dickinson). Cellular debris were eliminated from the analysis using a gate on the forward and side scatter. For each sample, 10,000 cells were collected.
Cytokine measurements. The production of IL-8, IL-6, and IL-12p40 was measured in supernatants collected 24 h after treatment. Levels of IL-8 and IL-6 in supernatants were measured using the BD CBA system and flow cytometry using a FACSCalibur flow cytometer (BD Biosciences). Data analysis was performed using the FCAP Array Software (BD Biosciences).
The production of IL-12p40 was measured using an enzyme-linked immunosorbent assay (ELISA) kit from R&D Systems. The levels of IL-8, IL-6, and IL-12p40 were calculated by using a standard curve obtained with recombinant IL-8 (5-5000 pg/ml), recombinant IL-6 (20-5000 pg/ml), or recombinant IL-12p40 (31.2-2000 pg/ml). The sensitivity of the methods was 5, 52, and 31 pg/ml for IL-8, IL-6, and IL-12p40, respectively.
Preparation of whole cell extract and DNA-binding assay. Following treatment with NiSO 4 or TNF-a, cells were lysed in Nonidet P-40 (NP-40) hypertonic lysis buffer. In brief, cell pellets from 8 3 10 6 cells were resuspended in buffer containing 0.2% (vol/vol) NP-40, 20% (vol/vol) Glycerol, 20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-KOH, pH 7.9, 420mM NaCl, 1mM dithiothreitol, 1mM sodium orthovanadate, 1mM sodium pyrophosphate, 0.125lM okadaic acid, 62.5mM EDTA, 40lM ethyleneglycol-bis(2-aminoethylether)-N,N,N#,N#-tetraacetic acid, 0.5mM PMSF, 1 lg/ml leupeptin, 1 lg/ml aprotinin, 1 lg/ml pepstatin, and incubated at 4°C for 30 min. Cellular debris were removed by centrifugation at 4°C, 17,600 g for 20 min. The DNA-binding assay was carried out as described previously (Wery-Zennaro et al., 1999) . In brief, the following 5# biotinlabeled single-stranded oligonucleotides were hybridized: 5#-TTG AGG GGA CTT TCC CAG G-3#, and 5#-CCT GGG AAA GTC CCC TCA A-3# (MWG) according to the human NF-jB promoter sequence. Mutated oligonucleotides (5#-TTG AGG CGA CTT TCC CAG G-3# and 5#-CCT GGG AAA GTC GCC TCA A-3#) were used for unspecific control binding. DNA-binding proteins were isolated from 200 lg of whole cell extracts at 4°C for 90 min with 2 lg double-stranded 5#-biotinylated oligonucleotides coupled to 50 ll of streptavidin-agarose beads (Sigma). Complexes were washed in binding buffer and eluted by boiling in reducing sample buffer. The binding proteins were separated on 8% SDS-PAGE followed by Western blot analysis using an antip65 mouse monoclonal Antibody (Santa Cruz Biotechnology).
Statistical analysis. Dunett's multicomparison modification of the Student's t-test was used to assess the statistical significance of experimental data for continuous variables. Experimental data were considered statistically different from control at p < 0.05.
RESULTS

NiSO 4 and DNCB Induce Phenotypical Changes in CD34-DC
Capacity of chemicals to induce the maturation of CD34-DC was assessed by determining the expression of key membrane proteins. CD34-DC generated from CD34 þ hematopoietic progenitors were cultured for 7 days with GM-CSF, TNF-a, and Flt-3L and incubated in the presence of either the water-soluble metal NiSO 4 or the DMSO-soluble organic chemical DNCB. CD83, CD86, HLA-DR, and CD40 expression was measured after 24 h. We first performed doseresponse studies to determine the optimal concentration of chemical for DC activation. The optimal concentrations could be defined as a concentration that modify DC phenotype with cell viability not under 75% viable cells. As seen in Figure 1A , CD83, CD86, HLA-DR, and CD40 expression was induced dose dependently after treatment with NiSO 4 . The maximal activation level was reached when NiSO 4 was tested at 500lM. In this experiment, cell viability remained unchanged at all the concentrations tested (data not shown).
DNCB was tested at 12.5, 25, and 50lM. The expression of CD83, CD86, HLA-DR, and CD40 was increased since 12.5lM and reached a maximum at 25lM of DNCB (Fig.  1B) . Although cell viability was not affected by the treatment with DNCB tested at 12.5lM, it was slightly diminished with 25lM of DNCB (75%) and dramatically affected at 50lM (47%), and corresponded to a loss of marker expression (Fig.  1B) . Considering that a minimum of 75% of cell must be viable to analyze the expression of cell surface markers and that 25lM seemed to be the concentration that induced the strongest expression of cell surface markers, we choose 25lM for testing DNCB for all the following experiments.
NiSO 4 (500lM) and DNCB (25lM) were then tested on the same donor. In Figure 2 and Table 1 , NiSO 4 displayed a major effect on CD83 and CD86 but also upregulated significantly HLA-DR and CD40. DNCB also induced the expression of CD83 and CD86. However, HLA-DR and CD40 were only slightly and not significantly affected in response to DNCB (Table 2) . Our results showed that NiSO 4 had a strong effect on CD83, CD86, HLA-DR, and CD40 expression, whereas DNCB affected mainly CD83 and CD86 expression.
Cytokine Production after Treatment with NiSO 4 or DNCB
Effect of various chemicals on cytokine production by CD34-DC was assessed using the same protocol as for phenotype analysis. Results showed that untreated DC did not produce IL-6 nor IL-12p40 whereas a basal level of IL-8 was detected (Table 3) . Upon NiSO 4 addition, DC produced large amounts of IL-6 and IL-12p40 and IL-8 secretion was significantly increased ( p < 0.05). However, in the presence of DNCB, only IL-8 production was augmented ( p < 0.01). These results clearly showed that NiSO 4 was able to induce the production of cytokines involved in DC function, whereas DNCB impact was limited to IL-8.
NiSO 4 but not DNCB Activates the NF-jB Pathway
Our observations indicated that NiSO 4 but not DNCB was able to upregulate protein expression such as surface CD40 or cytokine production such as IL-12p40, two events known to depend strongly on the NF-jB pathway (Laderach et al., . We therefore evaluated whether NiSO 4 or DNCB was able to activate the NF-jB pathway. Levels of IjB-a were determined by Western blotting on NiSO 4 -or DNCBstimulated CD34-DC. Results showed that IjB-a was degraded 15 min of NiSO 4 -treatment with a maximal degradation at 1 h (Fig. 3A) . IjB-a level was then gradually restored reaching control level at 4 h (Fig. 3C) . In contrast, no IjB-a degradation was observed in CD34-DC stimulated with DNCB at any time points measured (Figs. 3B and 3D) . Although IjB-a degradation was different between NiSO 4 -and DNCBstimulated cells, phosphorylation of p38 MAPK was detectable in response to both treatments demonstrating that DC All these results demonstrated that in contrast to NiSO 4 , DNCB failed to induce the degradation of IjB-a although the kinetic of p38 MAPK phosphorylation was similar in response to both chemicals. All these results were confirmed using a DNA-binding assay using specific NF-jB probes. This experiment showed the binding of the p65 subunit after NiSO 4 -treatment but not following DNCB treatment (Fig. 3E) .
Inhibition of NF-jB Activation Alters NiSO 4 -Induced DC Maturation
Using BAY 11-7085, a newly described inhibitor of the NF-jB pathway (Richter et al., 2001) , we investigated the consequences of NF-jB inhibition on NiSO 4 -stimulated CD34-DC phenotype. We first determined the optimal subtoxic dose of BAY 11-7085. As shown in Figure 4 , concentrations of 3 and 5lM of BAY 11-7085 significantly abolished the degradation of IjB-a induced by NiSO 4 . We chose to use 3lM BAY 11-7085 since this concentration had no effect on cell viability and on the phenotype of control untreated cells (Fig. 5) , whereas 5lM altered significantly cell viability (data not shown).
As reported in Figure 5 and Table 4 , BAY 11-7085 nearly abolished CD40 and HLA-DR increase generated by NiSO 4 and partially inhibited CD83 and CD86 upregulation (45 and 51%, respectively, when reported to the percentage of positive cells). In parallel, the effect of BAY 11-7085 was evaluated on cytokine production induced by NiSO 4 . BAY 11-7085 alone augmented the basal level of IL-8, whereas basal levels of IL-6 and IL-12p40 were not modified (Table 5) . Interestingly, the production of all these three cytokines induced by NiSO 4 was completely abolished by the treatment with BAY 11-7085 at 3lM (Table 5 ). These results suggest that the NF-jB pathway is strongly involved in cytokine production as well as in HLA-DR and CD40 expression and to a lesser extent in CD83 and CD86 expression in CD34-DC stimulated by NiSO 4 .
Effect of Inhibition of p38 MAPK on the IjB-a
Degradation Induced by NiSO 4
As previously described, both NiSO 4 and DNCB induced the phosphorylation of p38 MAPK . To evaluate a potential relationship between the p38 MAPK and the NF-jB pathways upon addition of NiSO 4 , CD34-DC were pretreated for 30 min with SB203580, a well-described pharmacological inhibitor of p38 MAPK, and further stimulated with NiSO 4 (500lM) for 1 h. As shown in Figure 6 , SB203580 had no effect on IjB-a degradation induced by NiSO 4 . This result showed that p38 MAPK did not regulate NiSO 4 -induced NF-jB activation suggesting that the two pathways are activated independently.
DNCB Inhibits NF-jB Activation by TNF-a
To further elucidate the absence of NF-jB activation in response to DNCB, we investigated the responsiveness of DC after TNF-a addition in the presence of DNCB. CD34-DC Note. Results are the mean fluorescence intensity of the cytometry study shown in Figure 2 corrected for the background intensity of isotype control antibodies (cMFI). Fold induction has been calculated as follows: cMFI of hapten-treated cells/cMFI of vehicle-treated cells.
TABLE 2 Expression of Surface Markers on NiSO 4 -and DNCB-Treated DC: Mean of Three Independent Experiments
Control NiSO 4 DMSO DNCB cMFI CD83 0.8 ± 0.1 6.0 ± 4.1* 1.5 ± 0.2 3.2 ± 0.7** CD86 3.1 ± 0.4 20.1 ± 6.2** 3.7 ± 0.1 15.0 ± 1.2*** HLA-DR 17.7 ± 5.4
39.6 ± 17.4* 20.9 ± 15.2 29.4 ± 20.1 CD40
1.6 ± 0.3 3.2 ± 1.3* 1.8 ± 0.3 3.7 ± 2.4 % Positive cells CD83 4 ± 1 5 9± 7*** 14 ± 3 2 9± 7* CD86 23 ± 2 7 7± 7*** 34 ± 6 6 4± 6** HLA-DR 75 ± 19 85 ± 13 78 ± 22 84 ± 19 CD40 15 ± 3 3 8± 8** 23 ± 9 2 6± 10 Note. Results are the mean ± SD of three independent experiments. The mean fluorescence intensity was corrected for the background intensity of isotype control antibodies (cMFI). ***p < 0.001, **p < 0.01, *p < 0.05. Note. At day 7, DC were treated with NiSO 4 (500lM) or with DNCB (25lM). IL-8 and IL-6 productions were determined in supernatants using flow cytometry as described in ''Materials and Methods'' section. IL-12p40 production was measured by ELISA. Cytokine production was measured after 24 h of treatment following the same protocol as for phenotype evaluation. Results represent the mean ± SD of three independent experiments. Results were expressed in ng/ml.
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were treated for 30 min with DNCB (25lM) and then further incubated for 15 min with 500 U/ml TNF-a, a concentration known to activate NF-jB (see Fig. 3 ). As shown in Figure 7 , treatment with DNCB of CD34-DC before TNF-a addition drastically decreased the IjB degradation observed in response to TNF-a alone. On the other hand, TNF-a-induced phosphorylation of p38 MAPK was not affected by DNCB treatment.
Since DNCB inhibited NF-jB activation, we asked the question about the impact of DNCB treatment on TNF-ainduced phenotypical changes of DC (Fig. 8) . Pretreatment of CD34-DC with DNCB, totally abolished the effect of TNF-a on HLA-DR expression (Table 6) . A partial inhibition of TNFa effect was observed with CD83 and CD40 in the presence of DNCB whereas TNF-a and DNCB displayed additive effects on CD86 and CCR7 expression. All these results suggested that the NF-jB pathway is important for CD83, CD40, and HLA-DR expression on DC stimulated with TNF-a. However, CD86 and CCR7 expression induced by TNF-a seemed to be regulated in a NF-jBindependent manner.
DISCUSSION
The key properties required for successful skin sensitization are the following: ability of the chemical to gain access to the viable epidermis, potential to form conjugates with protein to FIG. 5 . Inhibition of NF-jB activation altered surface marker expression on NiSO 4 -treated DC. CD34-DC were pretreated with BAY 11-7085 (3lM) for 1 h and further stimulated or not with NiSO 4 (500lM). Twenty-four hours after stimulation, cells were analyzed using flow cytometry for the expression of CD83, CD86, HLA-DR, and CD40. Results of a representative experiment out of four.
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create an immunogen, dermal trauma, and expression of skin cytokines involved in the induction of cutaneous immune response and recognition by T lymphocytes of the allergen complex displayed by immunostimulatory DCs.
DCs are activated by danger signals such as proinflammatory cytokines, bacterial products, and viruses. Haptens have also been demonstrated to induce the expression of markers related to function and maturation of DC, the production of proinflammatory cytokines, and the phosphorylation of members of the MAPK family. However, it is not clear if haptens are also able to activate the NF-jB pathway like danger signals.
In this study, NiSO 4 upregulated the expression of CD83, CD86, HLA-DR, and CD40 in CD34-DC. However, the effect of DNCB was limited to the expression of CD83 and CD86. Using MoDC, Staquet et al. (2004) have also observed that, in contrast to NiSO 4 , DNCB did not induce the expression of CD40. Several authors have also reported that DNCB compared to NiSO 4 is a weak inducer of HLA-DR expression (Aiba et al., 1997; De Smedt et al., 2005; Staquet et al., 2004) . Moreover, Aiba et al. (2000) showed that MoDC differentiated in the presence of transforming growth factor-b responded to DNCB by increasing the expression of CD86 and CD83 but not of HLA-DR.
In parallel to phenotypical changes, NiSO 4 showed a good capacity to induce the production of cytokines such as IL-6, IL-8, and IL-12p40 although DNCB only increased the production of IL-8. Several authors have also reported discrepancies in cytokine production between Nickel and DNCB. Aiba et al. (2003) have reported that NiCl 2 induced the production of IL-8 FIG. 6. p38 MAPK does not regulate NiSO 4 -induced NF-jB activation. CD34-DC were pretreated for 30 min with or without 20lM SB203580 and further treated in the presence or in the absence of 500lM NiSO 4 for 1 h. Cells were then lysed and probed for IjB-a level by Western blotting. Total p38 MAPK level was determined as a loading control. *Fold induction was determined as follows: normalized intensity of specific band in treated cells divided by the normalized intensity of in nontreated cells. Blots are representative of results obtained in three independent experiments.
FIG. 7.
DNCB inhibits TNF-a-induced IjB-a degradation. CD34-DC were pretreated in the presence or in the absence of DNCB (25lM) for 30 min and then further stimulated or not with TNF-a (500 U/ml) for 15 min. Cells were then lysed and probed for IjB-a level and phosphorylation of p38 MAPK by Western blotting. Total p38 MAPK level was determined as a loading control. *Fold induction was determined as follows: normalized intensity of specific band in treated cells divided by the normalized intensity of nontreated cells. Blots are representative of results obtained in three independent experiments. Note. CD34-derived DCs were pretreated in the presence or in the absence of BAY 11-7085 (3lM) for 1 h and further stimulated or not with NiSO 4 (500lM). IL-8 and IL-6 productions were determined in supernatants using flow cytometry as described in ''Materials and Methods'' section. IL-12p40 production was measured by ELISA. IL-8, IL-6, and IL-12p40 productions were measured after 24 h of treatment. Results of a representative experiment out of four. Results were expressed in ng/ml.
FIG. 8.
Effect of DNCB treatment on TNF-a-induced DC maturation. CD34-DC were pretreated in the presence or in the absence of DNCB (25lM) for 30 min, washed thrice, and further incubated for 24 h with TNF-a (500 U/ml). Cells were then analyzed using flow cytometry for the expression of CD83, CD86, HLA-DR, CD40, and CCR7. Results of a representative experiment out of three.
and IL-12p40 in MoDC, whereas DNCB only affected the production of IL-8. Furthermore, IL-6 has been also shown to be produced by MoDC in response to NiSO 4 but not to DNCB (Tuschl et al., 2000) . Recently, Verheyen et al. (2005) showed similar results in CD34-DC based on the messenger RNA expression of IL-8 and IL-6 in response to DNCB and NiCl 2 ; NiCl 2 induced both IL-8 and IL-6 gene expressions, whereas DNCB induced only IL-8 gene expression.
Based on these results, we hypothesized that differences observed between NiSO 4 and DNCB in DC maturation could involve the NF-jB pathway. IL-8, IL-12p40, CD83, and CD86 promoters contain NF-jB consensus sequences that are required for their expression (Berchtold et al. 2002; Hoffmann et al., 2002; Li et al., 2000; Yoshimoto et al., 1996) . Furthermore, using adenoviral transfert or inhibitors of IjB-a or RNAi for p50, NF-jB has been shown to be essential for HLA-DR, CD86, CD83, and CD40 expression as well as cytokine production such as IL-6, IL-12, and IL-8 in MoDC in response to LPS, TNF-a, and CD40L (Laderach et al., 2003; O'Sullivan and Thomas, 2002; Yoshimura et al., 2001) . Our results showed that NiSO 4 was able to induce the degradation of IjB-a as well as the binding of the p65 subunit on specific DNA probes. This effect was maximal after 1 h of stimulation with NiSO 4 . However, DNCB neither induced the degradation of IjB-a nor the binding of p65 on specific DNA probes. Aiba et al. (2003) have also observed in MoDC that nickel but not DNCB activated the phosphorylation of IjB-a with comparable kinetics. These results suggested that the difference in NF-jB activation observed between NiSO 4 and DNCB correlated to the differences in phenotype and in cytokine production observed with these two chemicals.
To test whether activation of NF-jB was involved in hapteninduced DC maturation, we used the inhibitor BAY 11-7085, known to block the phosphorylation of IjB-a and to prevent its degradation (Richter et al., 2001) . Experiments were conducted only on NiSO 4 -treated cells since DNCB does not activate NFjB in our model. We found that BAY 11-7085 effectively blocked NiSO 4 -induced IjB-a degradation in our model. In DC activated by NiSO 4 and treated with BAY 11-7085, increased expressions of HLA-DR and CD40 as well as IL-8, IL-6, and IL-12p40 production were nearly completely abrogated, but CD83 and CD86 potentialization was only partially inhibited. Using pyrrolidinedithiocarbamate, another inhibitor of NF-jB, Aiba et al. (2003) showed in MoDC a slight inhibition of CD86 and no effect on CD83 expression induced by nickel. To further elucidate the signaling pathway involved in NF-jB activation, we studied the relationship between p38 MAPK activation and NF-jB. It has previously been reported that stimulators of p38 MAPK, such as TNF-a can augment the activity of the NF-jB pathway via cross-talk between MKK6 and IKKb (Craig et al., 2000) . Our results showed that inhibition of p38 MAPK did not alter the degradation of IjB-a induced by NiSO 4 suggesting that p38 MAPK did not participate to this NF-jB activation by NiSO 4 in CD34-DC. This result is in agreement with recent papers reporting that p38 MAPK and NF-jB pathways are independent (Cloutier et al., in press ).
Our next question was to understand why DNCB did not activate the NF-jB pathway, whereas p38 MAPK was fully activated by this molecule. In the present study, we showed that pretreatment with DNCB blocked the degradation of IjB-a induced by TNF-a suggesting that DNCB acts as a potent inhibitor of the NF-jB pathway. Brennan and O'Neill (1998) have reported that DCNB, a structural analog of DNCB known to bind on thiol functions, blocked the activation of NF-jB by TNF-a in Jurkat cells. Other authors have also reported that curcumin and nordihydroguaiaritic acid, two CS, inhibited the degradation of IjB-a as we observed with DNCB (Brennan and O'Neill, 1998) . DNCB has also been previously described to be an irreversible inhibitor of thioredoxin reductase, leading to a strong activation of nicotinamide adenine dinucleotide phosphate, reduced oxidase, production of reactive oxygen intermediates (ROI), and suppression of NF-jB-dependent transcription in HELA cells (Arner et al., 1995; Nordberg et al., 1998) . As previously described for high concentrations of H 2 O 2 , strong production of ROI by DNCB could alter NF-jB activation by inhibiting nuclear translocation of NF-jB through preservation of cytoplasmic IjB-a levels (Korn et al., 2001) .
Alteration of the NF-jB pathway induced by DNCB resulted in a decrease in CD83, CD40, and HLA-DR expressions in DC treated with TNF-a. These results confirmed that expressions of CD83, CD40, and HLA-DR were dependent on NF-jB. Interestingly, CD86 expression induced by TNF-a was further augmented in the presence of DNCB. CD86 was the marker the less affected by treatment with BAY 11-7085 in NiSO 4 -treated DC suggesting that CD86 expression is less dependent on NF-jB. We have previously described that CCR7 expression was upregulated following exposure of CD34-DC to DNCB, and that an autocrine loop involving TNF-a was necessary . Here we showed that DNCB did not affect CCR7 expression induced by TNF-a confirming that TNF-a plays a role in CCR7 expression in a NF-jBindependent manner.
One important question remains if the effects we observed could reflect that DNCB is a potent allergen and irritant, whereas nickel is a moderate allergen and irritant. In human DCs, results obtained with irritants such as SDS or benzalkonium chloride did not show any phenotype modification or activation of signaling pathways such as MAPK or NF-jB (Aiba et al., 1997; De Smedt et al., 2001; Mizuashi et al., 2005) . In a recent paper, Toebak et al. (2005) have shown in MoDC that allergens were able to increase IL-8 secretion, whereas irritants rather decrease it. These results may suggest that DCs can distinguish a chemical irritant from a chemical sensitizer leading to the activation of specific signaling pathways. However, the strong irritant potential of DNCB is due to its capacity of inducing oxidative stress leading to the activation of JNK and p38 MAPK and this event is directly linked to DC phenotype alteration (Aiba et al., 2003; Boisleve et al., 2004) . Indeed, Aiba et al. have shown in MoDC that DNCB is more potent than NiCl 2 for reducing the GSH/GSSG ratio (Mizuashi et al., 2005) and the authors suggested a correlation with p38 MAPK activation. On the other hand, Handley et al. (2005) have shown that H 2 O 2 generates a strong oxidative stress without altering DC phenotype. All these results suggest that sensitizers probably need to produce some oxidative stress to activate DC but this property is not sufficient to induce full DC maturation.
In summary, our results suggested a causal relationship between activation of NF-jB by chemical sensitizers and alteration of DC phenotype. NiSO 4 activates NF-jB and inducing extensive modifications of DC phenotype. However, DNCB induced the expression of CD86, CD83, CCR7, and the production of IL-8 without activating NF-jB suggesting that other signaling pathways such as MAPK are mainly involved. The signaling pathways involved upon NiSO 4 or DNCB exposure provide an explanation for the phenotypical differences observed in DC maturation induced by these two CS.
Finally, a figure showing the signaling pathways already identified as being involved in the activation of DC by CS, as well as their possible interactions, is proposed in Figure 9 . 
